NCT02895061View on ClinicalTrials.gov

Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.

NACompletedINTERVENTIONAL

Enrollment

502

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

January 31, 2016

Conditions

Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis

Interventions

DRUG

Alfacalcidol

Alfacalcidol 1 microgram/capsule

All Listed Sponsors

lead

Phramongkutklao College of Medicine and Hospital

OTHER

NCT02895061 - Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients. | Biotech Hunter | Biotech Hunter